Last reviewed · How we verify
KINE-101
At a glance
| Generic name | KINE-101 |
|---|---|
| Sponsor | Kine Sciences Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP (PHASE1)
- A First-in-Human Study of KINE-101 in Healthy Volunteers (PHASE1)
- A Phase 1 MAD Study of KINE-101 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KINE-101 CI brief — competitive landscape report
- KINE-101 updates RSS · CI watch RSS
- Kine Sciences Co., Ltd. portfolio CI